Infinity Starts Trial of Hedgehog Pathway Blocker

Luke Timmerman10/16/08

Infinity Pharmaceuticals, the Cambridge, MA-based developer of cancer drugs, said today it has started an early-stage clinical trial of 30 to 50 patients with advanced solid tumors, or those that have spread. The company (NASDAQ: INFI) will test IPI-926, an orally-given blocker of the hedgehog pathway, which researchers say can play a central role in tumor growth when it becomes overactivated.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.